Oncocyte CEO Ronald Andrews steps down; Joshua Riggs named Interim CEO, Louis Silverman appointed to board

Insight Molecular Diagnostics Inc.

Ronald Andrews resigns as President, CEO, and director, effective Dec 1, 2022.
Joshua Riggs, previously General Manager Transplant, appointed Interim CEO effective Dec 2, 2022.
Andrews receives severance: $500K cash, 12 months COBRA ($40,128), accelerated vesting of equity.
Andrews to provide consulting services through Feb 28, 2023; receives stock options for 50,000 shares.
Board appoints Louis Silverman as director; he is CEO of Hicuity Health, former CEO of Quality Systems.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ronald Andrews

President and Chief Executive Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-12-01
Successor: Joshua Riggs
Filed: December 5, 2022, 6:59 PM ET

On November 30, 2022, Oncocyte Corporation (the “Company”) issued a press release announcing that Ronald Andrews will step down from his role as President and Chief Executive Officer and director of the Board of Directors of the Company (the “Board”), effective as of December 1, 2022

Appointed (interim)

Joshua Riggs

Interim Chief Executive Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-12-02
Filed: December 5, 2022, 6:59 PM ET

and the appointment of Joshua Riggs as Interim Chief Executive Officer of the Company, effective as of December 2, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Andrews departed as President and Chief Executive Officer at Insight Molecular Diagnostics Inc..

Action: step down
Role: President and Chief Executive Officer

Exact text from the filing

On November 30, 2022, Oncocyte Corporation (the “Company”) issued a press release announcing that Ronald Andrews will step down from his role as President and Chief Executive Officer and director of the Board of Directors of the Company (the “Board”), effective as of December 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Riggs was appointed as Interim Chief Executive Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

and the appointment of Joshua Riggs as Interim Chief Executive Officer of the Company, effective as of December 2, 2022.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-034460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.